Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Eligo Bioscience

Eligo Bioscience
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
$20M LATEST DEAL AMOUNT
8 INVESTORS
Description

Developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.

Website
Formerly Known As
PhageX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 29 rue du Faubourg Saint-Jacques
  • 75014 Paris
  • France
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Eligo Bioscience’s full profile, request a free trial.

Eligo Bioscience Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC (Series A) 26-Sep-2017 $20M 000.00 Completed Generating Revenue
6. Grant 20-Sep-2016 00.000 Completed Generating Revenue
5. Early Stage VC (Series A) 04-Aug-2016 00.000 00.000 000.00 Completed Generating Revenue
4. Grant 09-Feb-2015 00000 Completed Generating Revenue
3. Grant 08-Jun-2014 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Eligo Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
A 000,000 00.0 00.0 00 00.0 00.000
To view this company’s complete Cap Table, request access »

Eligo Bioscience Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
Khosla Ventures Venture Capital Minority 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Seventure Partners Venture Capital Minority 000 0000 000000 0
Tremplin Entreprises Other 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Eligo Bioscience Executive Team (5)

Name Title Board
Seat
Contact
Info
Xavier Duportet Ph.D Co-Founder, Chief Executive Officer and Chairman
Bertrand Lellouche Chief Financial Officer
David Bikard Ph.D Co-Founder, Chief Scientific Officer and Board Member
Timothy Lu Ph.D Co-Founder & Advisor
Luciano Marraffini Ph.D Co-Founder

Eligo Bioscience Board Members (2)

Name Representing Role Since Contact
Info
Jean-Pierre Lehner Eligo Bioscience Board Member 000 0000
Sebastien Groyer Ph.D Seventure Partners Board Member 000 0000